News > Bharat Biotech to enhance manufacturing capacity of Covaxin, aims additional 200M doses per annum

Bharat Biotech to enhance manufacturing capacity of Covaxin, aims additional 200M doses per annum

India Infoline | 22/05/2021 12:52 PM | Click to read full article

The company announced that about 200 million additional doses will be produced from its subsidiary unit in Gujarat. Bharat Biotech's wholly-owned subsidiary Chiron Behring Vaccines has enhanced the production capacity of Covaxin in Gujarat's Ankleshwar unit.

The company targets 200 million doses per annum from the GMP facility which is already operational for the production of vaccines depending upon inactivated vero cell platform technology, as per Bharat Biotech in a statement.